Aprecia Pharmaceuticals
Aprecia uses 3DP technology for commercial-scale, pharmaceutical manufacturing. Its 3DP technology includes a multipatented binder-jetting manufacturing system, allowing for both open-bed and in-cavity printing. Its ZipDose technology platform creates rapidly disintegrating oral dosage forms.
Aprecia Pharmaceuticals uses 3D printing (3DP) technology for commercial-scale, pharmaceutical manufacturing, for which it received the first and only US FDA-approved 3DP pharmaceutical product approval in 2015 . The company’s proprietary 3DP technology includes a multipatented binder-jetting manufacturing system, allowing for both open-bed and in-cavity printing, as well as their advanced formulation and rapid-prototyping platforms. The ZipDose technology platform creates rapidly disintegrating oral dosage forms that are easy to take and easy to administer.
Aprecia licenses its exclusive technology platform to pharmaceutical partners as a means to extend product lines, improve patient reach and experience, and address FDA requirements as a paediatric delivery form.
Aprecia is privately held and was founded in 2003.
